60
Participants
Start Date
May 20, 2018
Primary Completion Date
October 25, 2024
Study Completion Date
October 25, 2024
Evolocumab
420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
Placebo
Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
Steven Paul Schulman, Baltimore
Collaborators (1)
Amgen
INDUSTRY
Johns Hopkins University
OTHER